SYNTHETIC BIOLOG.DL -,001
SYNTHETIC BIOLOG.DL -,001
Share · US87164U4094 · TOVX (LSSI)
Overview Financial Indicators
0,44 EUR
3,07 % 0,01 EUR
Lang & Schwarz (XNYS) · Current prices and charts at MoneyPeak
10.06.2025 19:29

Current Prices from SYNTHETIC BIOLOG.DL -,001

ExchangeTickerCurrencyLast TradePriceDaily Change
XNYS: NYSE
NYSE
TOVX
USD
10.06.2025 19:29
0,50 USD
0,48 USD
+4,17 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
2,87 % 9,64 % -5,35 % -65,26 % -64,83 % -92,86 % -99,55 %

Firmenprofil zu SYNTHETIC BIOLOG.DL -,001 Aktie

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.

Unternehmensdaten

Name SYNTHETIC BIOLOG.DL -,001
Firma Theriva Biologics, Inc.
Symbol TOVX
Website https://therivabio.com
Heimatbörse LSSI Lang & Schwarz
ISIN US87164U4094
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Steven A. Shallcross CPA
Land Vereinigte Staaten von Amerika
Währung EUR
Mitarbeiter 0,0 T
Adresse 9605 Medical Center Drive, 20850 Rockville
IPO Datum 2006-12-18

Aktien-Splits

Datum Split
26.08.2024 1:25

Kennungs-Wechsel

Datum Von Zu
13.10.2022 SYN TOVX
17.02.2012 AEN SYN

Ticker Symbole

Name Symbol
Frankfurt SFY.F
NYSE TOVX

Weitere Aktien

Investoren die SYNTHETIC BIOLOG.DL -,001 die halten, haben auch folgende Aktien im Depot:
PERNOD RICA. 23/27 MTN
PERNOD RICA. 23/27 MTN Anleihe
PROSHARES PET CARE ETF
PROSHARES PET CARE ETF ETF
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025